原发性肝癌根治性切除术后的综合治疗

目的探讨原发性肝癌根治性切除术后,实施TACE、生物治疗及PEI、RFA对肝内复发率及生存率的影响。方法将42例原发性肝癌根治性切除术后患者分成观察组和对照组,观察组22例行综合治疗,包括:术后TACE、生物治疗及PEI、RFA,对照组20例仅予对症、支持治疗。对两组病例的1、2年肝内复发率和生存率分别进行X2检验。结果观察组1、2年的肝内复发率为13.6%,31.8%,对照组为40.0%及65.0%,而观察组1、2年生存率90.9%,68.2%,对照组为65.0%及35.0%。两组差异有显著性(P<0.05)。结论原发性肝癌根治性切除术后联合TACE、生物治疗及PEI、RFA的综合治疗方案可降低肝内复发率,提高生存率。

Comparehensive treatment of primary liver cancer after radical resection

Objective To explore the effect of neoadjuvant combined postoperative therapy on patients with hepatocellular carcinoma after radical resection. Methods 42 postoperative case divided into 2 groups at random with 22 cases receiving hepatic artery chemotherapy and biotherapy, and 20 cases receiving supporting treatment only. Results The intrahepatic tumor recurrence rate at 1 year and 2 year in treatment group was 13.6% and 31.8%,compared with 40.0% and 65.0% in control group(p<0.05). The survival rate in the former was 90.9% and 68.2% respectively, compared with that of 65.0% and 35.0% in the later (p<0.05). Conclusions This neoadjuvant combined postoperative theropy effects a low recurrency and long survival in HCC patients after radical resection.